2016 | Abbvie | Synagis - 100 mg/vial | palivizumab | 02438364 | Respiratory Syncytial Virus | 7 Nov 2016 | Within Guidelines |
2016 | Abbvie | Synagis - 50 mg/vial | palivizumab | 02438372 | Respiratory Syncytial Virus | 3 Nov 2016 | Within Guidelines |
2016 | Abbvie | Venclexta - 10 mg/tablet | venetoclax | 02458039 | Cancer | 31 Oct 2016 | Within Guidelines |
2016 | Abbvie | Venclexta - 50 mg/tablet | venetoclax | 02458047 | Cancer | 31 Oct 2016 | Within Guidelines |
2016 | Abbvie | Venclexta - 100 mg/tablet | venetoclax | 02458055 | Cancer | 2 Nov 2016 | Within Guidelines |
2016 | Abbvie | Venclexta 10/50/100 - 1 N.A./kit | venetoclax | 02458063 | Cancer | 31 Oct 2016 | Within Guidelines |
2016 | Abbvie | Humira - 40 mg/syringe | adalimumab | 02458349 | Rheumatoid Arthritis | 16 Nov 2016 | VCU |
2016 | Abbvie | Humira - 40 mg/pen | adalimumab | 02458357 | Rheumatoid Arthritis | 16 Nov 2016 | VCU |
2016 | Acerus Pharmaceuticals SRL | Natesto - 5.5 mg/actuation | testosterone nasal gel | 02450550 | Hypogonadism | 6 May 2016 | Within Guidelines |
2016 | Actelion Pharmaceuticals Canada Inc. | Uptravi - 200 mg/tablet | selexipag | 02451158 | Hypertension | 21 Apr 2016 | Within Guidelines |
2016 | Actelion Pharmaceuticals Canada Inc. | Uptravi - 400 mg/tablet | selexipag | 02451166 | Hypertension | 21 Apr 2016 | Within Guidelines |
2016 | Actelion Pharmaceuticals Canada Inc. | Uptravi - 600 mg/tablet | selexipag | 02451174 | Hypertension | 21 Apr 2016 | Within Guidelines |
2016 | Actelion Pharmaceuticals Canada Inc. | Uptravi - 800 mg/tablet | selexipag | 02451182 | Hypertension | 21 Apr 2016 | Within Guidelines |
2016 | Actelion Pharmaceuticals Canada Inc. | Uptravi - 1000 mg/tablet | selexipag | 02451190 | Hypertension | 21 Apr 2016 | Within Guidelines |
2016 | Actelion Pharmaceuticals Canada Inc. | Uptravi - 1200 mg/tablet | selexipag | 02451204 | Hypertension | 21 Apr 2016 | Within Guidelines |
2016 | Actelion Pharmaceuticals Canada Inc. | Uptravi - 1400 mg/tablet | selexipag | 02451212 | Hypertension | 21 Apr 2016 | Within Guidelines |
2016 | Actelion Pharmaceuticals Canada Inc. | Uptravi - 1600 mg/tablet | selexipag | 02451220 | Hypertension | 21 Apr 2016 | Within Guidelines |
2016 | Alexion Pharmaceuticals Inc. | Strensiq - 18 mg/vial | asfotase alfa | 02444615 | Paediatric-onset Hypophosphatasia | 20 Oct 2015 (Patented 21 Jun 2016) | Subject to Investigation |
2016 | Alexion Pharmaceuticals Inc. | Strensiq - 80 mg/vial | asfotase alfa | 02444658 | Paediatric-onset Hypophosphatasia | 17 Feb 2016 | Subject to Investigation |
2016 | Allergan Inc. | Fetzima - 80 mg/capsule | levomilnacipran | 02440997 | Antidepressant | 22 Apr 2016 | Within Guidelines |
2016 | Allergan Inc. | Fetzima - 120 mg/capsule | levomilnacipran | 02441004 | Antidepressant | 22 Apr 2016 | Within Guidelines |
2016 | Allergan Inc. | Belkyra - 10 mg/mL | deoxycholic acid | 02443910 | Submental Fat | 26 Jan 2016 | Within Guidelines |
2016 | Amgen Canada Inc. | Neupogen - 0.6 mg/mL | filgrastim | 02420104 | Cancer | 28 Jan 2016 | Does Not Trigger Investigation |
2016 | Amgen Canada Inc. | Neupogen - 0.6 mg/mL | filgrastim | 02420112 | Cancer | 2 Feb 2016 | Within Guidelines |
2016 | Amgen Canada Inc. | Blincyto - 38.5 mcg/vial | blinatumomab | 02450283 | Cancer | 17 Mar 2016 | Within Guidelines |
2016 | Amgen Canada Inc. | Kyprolis - 60 mg/vial | carfilzomin | 02451034 | Cancer | 11 Feb 2016 | Within Guidelines |
2016 | AstraZeneca Canada Inc. | Bydureon - 2 mg/dose | exenatide | 02448610 | Diabetes | 16 Feb 2016 | Within Guidelines |
2016 | AstraZeneca Canada Inc. | Xigduo 5/1000 - 1005 mg/tablet | dapagliflozin / metformin hydrochloride | 02449943 | Diabetes | 8 Feb 2016 | Within Guidelines |
2016 | AstraZeneca Canada Inc. | Lynparza - 50 mg/capsule | olaparib | 02454408 | Cancer | 16 May 2016 | Subject to Investigation |
2016 | AstraZeneca Canada Inc. | Xigduo 5/850 - 855 mg/tablet | dapagliflozin / metformin hydrochloride | 02449935 | Diabetes | 9 Feb 2016 | Within Guidelines |
2016 | AstraZeneca Canada Inc. | Brilinta - 60 mg/tablet | ticagrelor | 02455005 | Atherothrombosis | 13 Jun 2016 | Within Guidelines |
2016 | AstraZeneca Canada Inc. | Tagrisso - 40 mg/tablet | osimertinib | 02456214 | Cancer | 19 Jul 2016 | Within Guidelines |
2016 | AstraZeneca Canada Inc. | Tagrisso - 80 mg/tablet | osimertinib | 02456222 | Cancer | 19 Jul 2016 | Within Guidelines |
2016 | Bayer Inc. | Kovaltry | antihemophilic factor (recombinant) | 02451441 | Hemophilia | 16 Jun 2016 | Within Guidelines |
2016 | Bayer Inc. | Kovaltry | antihemophilic factor (recombinant) | 02451468 | Hemophilia | 16 Jun 2016 | Within Guidelines |
2016 | Bayer Inc. | Kovaltry | antihemophilic factor (recombinant) | 02451476 | Hemophilia | 16 Jun 2016 | Within Guidelines |
2016 | Bayer Inc. | Kovaltry | antihemophilic factor (recombinant) | 02451484 | Hemophilia | 16 Jun 2016 | Within Guidelines |
2016 | Bayer Inc. | Kovaltry | antihemophilic factor (recombinant) | 02451492 | Hemophilia | 16 Jun 2016 | Within Guidelines |
2016 | Bioverativ Canada Inc. | Alprolix - 500 IU/vial | coagulatoin factor IX (recombinant) | 02422913 | Hemophilia | 15 Dec 2015 (Patented 9 Aug 2016) | Within Guidelines |
2016 | Bioverativ Canada Inc. | Alprolix - 1000 IU/vial | coagulatoin factor IX (recombinant) | 02422921 | Hemophilia | 20 Jan 2016 (Patented 9 Aug 2016) | Within Guidelines |
2016 | Bioverativ Canada Inc. | Alprolix - 2000 IU/vial | coagulatoin factor IX (recombinant) | 02422948 | Hemophilia | 15 Dec 2015 (Patented 9 Aug 2016) | Within Guidelines |
2016 | Bioverativ Canada Inc. | Alprolix - 3000 IU/vial | coagulatoin factor IX (recombinant) | 02422956 | Hemophilia | 20 Dec 2015 (Patented 9 Aug 2016) | Within Guidelines |
2016 | Bioverativ Canada Inc. | Eloctate - 3000 IU/vial | Antihemophilic factor (Recombinant, B-domain deleted) | 02430355 | Hemophilia | 20 Jan 2016 (Patented 9 Aug 2016) | Within Guidelines |
2016 | Bioverativ Canada Inc. | Eloctate - 2000 IU/vial | Antihemophilic factor (Recombinant, B-domain deleted) | 02430347 | Hemophilia | 20 Jan 2016 (Patented 9 Aug 2016) | Within Guidelines |
2016 | Bioverativ Canada Inc. | Eloctate - 1500 IU/vial | Antihemophilic factor (Recombinant, B-domain deleted) | 02430339 | Hemophilia | 20 Jan 2016 (Patented 9 Aug 2016) | Within Guidelines |
2016 | Bioverativ Canada Inc. | Eloctate - 1000 IU/vial | Antihemophilic factor (Recombinant, B-domain deleted) | 02430320 | Hemophilia | 20 Jan 2016 (Patented 9 Aug 2016) | Within Guidelines |
2016 | Bioverativ Canada Inc. | Eloctate - 750 IU/vial | Antihemophilic factor (Recombinant, B-domain deleted) | 02430312 | Hemophilia | 20 Jan 2016 (Patented 9 Aug 2016) | Within Guidelines |
2016 | Bioverativ Canada Inc. | Eloctate - 500 IU/vial | Antihemophilic factor (Recombinant, B-domain deleted) | 02430304 | Hemophilia | 20 Jan 2016 (Patented 9 Aug 2016) | Within Guidelines |
2016 | Bioverativ Canada Inc. | Eloctate - 250 IU/vial | Antihemophilic factor (Recombinant, B-domain deleted) | 02430290 | Hemophilia | 20 Jan 2016 (Patented 9 Aug 2016) | Within Guidelines |
2016 | Boehringer Ingelheim (Canada) Ltd. | Synjardy 12.5/1000 - 1012.5 mg/tablet | empagliflozin/meformin hydrochloride | 02456621 | Diabetes | 3 Aug 2016 | Within Guidelines |
2016 | Boehringer Ingelheim (Canada) Ltd. | Synjardy 12.5/500 - 512.5 mg/tablet | empagliflozin/meformin hydrochloride | 02456605 | Diabetes | 3 Aug 2016 | Within Guidelines |
2016 | Boehringer Ingelheim (Canada) Ltd. | Synjardy 12.5/850 - 862.5 mg/tablet | empagliflozin/meformin hydrochloride | 02456613 | Diabetes | 3 Aug 2016 | Within Guidelines |
2016 | Boehringer Ingelheim (Canada) Ltd. | Synjardy 5/1000 - 1005 mg/tablet | empagliflozin/meformin hydrochloride | 02456591 | Diabetes | 3 Aug 2016 | Within Guidelines |
2016 | Boehringer Ingelheim (Canada) Ltd. | Synjardy 5/500 - 505 mg/tablet | empagliflozin/meformin hydrochloride | 02456575 | Diabetes | 3 Aug 2016 | Within Guidelines |
2016 | Boehringer Ingelheim (Canada) Ltd. | Synjardy 5/850 - 855 mg/tablet | empagliflozin/meformin hydrochloride | 02456583 | Diabetes | 3 Aug 2016 | Within Guidelines |
2016 | Bristol-Myers Squibb Canada Co. | Sunvepra - 100 mg/capsule | asunaprevir | 02452294 | Hepatitis C | 22 Apr 2016 | Within Guidelines |
2016 | Bristol-Myers Squibb Canada Co. | Evotaz - 450 mg/tablet | atazanavir sulphate/ cobicistat | 02446731 | HIV | 11 Feb 2016 | Within Guidelines |
2016 | Cipher Pharmaceuticals Inc. | Beteflam - 2.25 mg/patch | betamethasone valerate | 02449773 | Psoriasis | 6 Apr 2016 | Within Guidelines |
2016 | Duchesnay Inc. | Pregvit | multivitamins and minerals | 02451573 | Dietary Supplement | 6 Jul 2016 | Within Guidelines |
2016 | Duchesnay Inc. | Pregvit Folic 5 | multivitamins and minerals | 02451581 | Dietary Supplement | 31 Aug 2016 | Within Guidelines |
2016 | Eisai Limited | Lenvima - 10 mg/day | lenvatinib mesylate | 02450321 | Cancer | 29 Jul 2016 | Within Guidelines |
2016 | Eisai Limited | Lenvima 10/10 - 20 mg/day | lenvatinib mesylate | 02450305 | Cancer | 13 Apr 2016 | Within Guidelines |
2016 | Eisai Limited | Lenvima 10/10/4 - 24 mg/day | lenvatinib mesylate | 02450291 | Cancer | 13 Apr 2016 | Within Guidelines |
2016 | Eisai Limited | Lenvima 10/4 - 14 mg/day | lenvatinib mesylate | 02450313 | Cancer | 13 Apr 2016 | Within Guidelines |
2016 | Eli Lilly Canada Inc. | Trulicity - 0.75 mg/pen | dulaglutide | 02448599 | Diabetes | 8 Jan 2016 | Within Guidelines |
2016 | Eli Lilly Canada Inc. | Taltz - 80 mg/mL | ixekizumab | 02455102 | Psoriasis | 11 Aug 2016 | Within Guidelines |
2016 | Eli Lilly Canada Inc. | Taltz - 80 mg/mL | ixekizumab | 02455110 | Psoriasis | 11 Aug 2016 | Within Guidelines |
2016 | Ferring Inc. | Cortiment - 9 mg/tablet | budesonide | 02455889 | Ulcerative colitis | 25 Jul 2016 | Within Guidelines |
2016 | Galderma Canada Inc. | TactuPump Forte - 70 g/pump | adapalene/ benzoyl peroxide | 02446235 | Acne | 4 Jan 2016 | Within Guidelines |
2016 | Gilead Sciences Inc. | Genvoya 200/150/150/10 - 510 mg/tablet | elvitegravir / cobicistat / emtricitabine / tefofovir alafenamide | 02449498 | HIV | 3 Feb 2016 | VCU |
2016 | Gilead Sciences Inc. | Epclusa 400/100 - 500 mg/tablet | sofosbuvir/velpatasvir | 02456370 | Hepatitis C | 2 Aug 2016 | Within Guidelines |
2016 | Gilead Sciences Inc. | Descovy 200/10 - 210 mg/tablet | emtricitabine/tenofovir alafenamide | 02454416 | HIV | 3 Jun 2016 | Within Guidelines |
2016 | Gilead Sciences Inc. | Descovy 200/25 - 225 mg/tablet | emtricitabine/tenofovir alafenamide | 02454424 | HIV | 3 Jun 2016 | Within Guidelines |
2016 | GlaxoSmithKline Inc. | Menjugate Liquid | meningococcal group C conjugate vaccine | 02440709 | Vaccine | 7 Oct 2015 (Patented 16 Aug 2016) | Within Guidelines |
2016 | GlaxoSmithKline Inc. | Arnuity Ellipta - 100 mcg/dose | fluticasone furoate | 02446561 | Asthma | 26 Jan 2016 | Within Guidelines |
2016 | GlaxoSmithKline Inc. | Arnuity Ellipta - 200 mcg/dose | fluticasone furoate | 02446588 | Asthma | 14 Dec 2015 | Within Guidelines |
2016 | Hoffman-La Roche Limited | Cotellic - 20 mg/tablet + Zelboraf – 240 mg/tablet | cobimetinib | 02452340 | Cancer | 6 Apr 2016 | Within Guidelines |
2016 | Hoffman-La Roche Limited | Rituxan SC - 120 mg/mL | rituximab | 02457350 | Cancer | 22 Nov 2016 | Within Guidelines |
2016 | Hospira Healthcare Corporation (Canada) | Precedex - 4 mcg/mL | dexmedetomidine hydrochloride | 02437147 | Sedation | 9 May 2016 | Within Guidelines |
2016 | Janssen Inc. | Zytiga - 500 mg/tablet | abiraterone acetate | 02457113 | Cancer | 13 Oct 2016 | Does Not Trigger Investigation |
2016 | Janssen Inc. | Invega Trinza - 175 mg/syringe | paliperidone palmitate | 02455943 | Schizophrenia | 2 Aug 2016 | Within Guidelines |
2016 | Janssen Inc. | Invega Trinza - 263 mg/syringe | paliperidone palmitate | 02455986 | Schizophrenia | 2 Aug 2016 | Within Guidelines |
2016 | Janssen Inc. | Invega Trinza - 350 mg/syringe | paliperidone palmitate | 02455994 | Schizophrenia | 2 Aug 2016 | Within Guidelines |
2016 | Janssen Inc. | Invega Trinza - 525 mg/syringe | paliperidone palmitate | 02456001 | Schizophrenia | 2 Aug 2016 | Within Guidelines |
2016 | Janssen Inc. | Invokamet 150/1000 - 1150 mg/tablet | canagliflozin/metformin hydrochloride | 02455455 | Diabetes | 13 Jul 2016 | Within Guidelines |
2016 | Janssen Inc. | Invokamet 150/500 - 650 mg/tablet | canagliflozin/metformin hydrochloride | 02455439 | Diabetes | 13 Jul 2016 | Within Guidelines |
2016 | Janssen Inc. | Invokamet 150/850 - 1000 mg/tablet | canagliflozin/metformin hydrochloride | 02455447 | Diabetes | 13 Jul 2016 | Within Guidelines |
2016 | Janssen Inc. | Invokamet 50/1000 - 1050 mg/tablet | canagliflozin/metformin hydrochloride | 02455420 | Diabetes | 13 Jul 2016 | Within Guidelines |
2016 | Janssen Inc. | Invokamet 50/500 - 550 mg/tablet | canagliflozin/metformin hydrochloride | 02455404 | Diabetes | 13 Jul 2016 | Within Guidelines |
2016 | Janssen Inc. | Invokamet 50/850 - 900 mg/tablet | canagliflozin/metformin hydrochloride | 02455412 | Diabetes | 13 Jul 2016 | Within Guidelines |
2016 | Leo Pharma Inc. | Enstilar - 1 N.A./dose | calcipotriol/betamethasone | 02457393 | Psoriasis | 11 Nov 2016 | Within Guidelines |
2016 | Merck Canada Inc. | Zerbaxa 1000/500 - 1500 mg/vial | ceftolozane / tazobactam | 02446901 | Antibiotic | 12 Jan 2016 | Within Guidelines |
2016 | Merck Canada Inc. | Brenzys - 50 mg/mL | etanercept | 02455331 | Rheumatoid arthritis | 23 Sep 2016 | Within Guidelines |
2016 | Merck Canada Inc. | Brenzys - 50 mg/mL | etanercept | 02455323 | Rheumatoid arthritis | 23 Sep 2016 | Within Guidelines |
2016 | Merck Canada Inc. | Zepatier 50/100 - 150 mg/tablet | elbasvir / grazoprevir | 02451131 | Hepatitis C | 25 Jan 2016 | VCU |
2016 | Merck Canada Inc. | Bridion - 100 mg/mL | sugammadex | 02451816 | Selective Relaxant Binding Agent | 19 Feb 2016 | VCU |
2016 | Novartis Pharma Canada Inc. | Afinitor - 7.5 mg/tablet | everolimus | 02450267 | Cancer | 05 Apr 2016 | Does Not Trigger Investigation |
2016 | Novartis Pharma Canada Inc. | Signifor LAR - 20 mg/vial | pasireotide | 02437252 | Acromegaly | 28 Jan 2016 | Within Guidelines |
2016 | Novartis Pharma Canada Inc. | Jadenu - 90 mg/tablet | deferasirox | 02452219 | Chronic iron overload | 24 Mar 2016 | Within Guidelines |
2016 | Novartis Pharma Canada Inc. | Jadenu - 180 mg/tablet | deferasirox | 02452227 | Chronic iron overload | 24 Mar 2016 | Within Guidelines |
2016 | Novartis Pharma Canada Inc. | Jadenu - 360 mg/tablet | deferasirox | 02452235 | Chronic iron overload | 24 Mar 2016 | Within Guidelines |
2016 | Octapharma Canada Inc. | Nuwiq - 250 unit/vial | Antihemophilic factor (Recombinant, B-domain deleted), Antihemorrhagic Blood Coagulation Factor VIII | 02432951 | Hemophilia | 22 Dec 2015 | Within Guidelines |
2016 | Octapharma Canada Inc. | Nuwiq - 500 unit/vial | Antihemophilic factor (Recombinant, B-domain deleted), Antihemorrhagic Blood Coagulation Factor VIII | 02432978 | Hemophilia | 22 Dec 2015 | Within Guidelines |
2016 | Octapharma Canada Inc. | Nuwiq - 2000 IU/Vial | Antihemophilic factor (Recombinant, B-domain deleted), Antihemorrhagic Blood Coagulation Factor VIII | 02432994 | Hemophilia | 14 Jul 2016 | Within Guidelines |
2016 | Octapharma Canada Inc. | Nuwiq - 1000 IU/Vial | Antihemophilic factor (Recombinant, B-domain deleted), Antihemorrhagic Blood Coagulation Factor VIII | 02432986 | Hemophilia | 21 Jul 2016 | Within Guidelines |
2016 | Paladin Labs Inc. | Iclusig - 45 mg/tablet | ponatinib | 02437341 | Cancer | 7 Jan 2016 | Within Guidelines |
2016 | Pendopharm, Division of Pharmascience Inc. | Vibativ - 750 mg/vial | telavancin hydrochloride | 02330725 | Antibiotic | 6 Jan 2016 | Within Guidelines |
2016 | Pfizer Canada Inc. | Somavert - 25 mg/vial | pegvisomant | 02448831 | Acromegaly | 10 Mar 2016 | Within Guidelines |
2016 | Pfizer Canada Inc. | Somavert - 30 mg/vial | pegvisomant | 02448858 | Acromegaly | 10 Mar 2016 | Within Guidelines |
2016 | Pfizer Canada Inc. | Ibrance - 75 mg/capsule | palbociclib | 02453150 | Cancer | 20 Apr 2016 | Within Guidelines |
2016 | Pfizer Canada Inc. | Ibrance - 100 mg/capsule | palbociclib | 02453169 | Cancer | 19 Apr 2016 | Within Guidelines |
2016 | Pfizer Canada Inc. | Ibrance - 125 mg/capsule | palbociclib | 02453177 | Cancer | 19 Apr 2016 | Within Guidelines |
2016 | PTC Therapeutics International Limited | Translarna - 1,000 mg/pouch | ataluren | | Duchenne muscular dystrophy | 8 Feb 2016 | Within Guidelines |
2016 | Purdue Pharma | BuTrans - 15 mg/patch | buprenorphine | 02450771 | Pain | 15 Jun 2016 | Does Not Trigger Investigation |
2016 | Servier Canada Inc. | Viacoram 3.5/2.5 - 6 mg/tablet | perindopril arginine/amlodipine | 02451530 | Hypertension | 05 Apr 2016 | Within Guidelines |
2016 | Servier Canada Inc. | Viacoram 7/5 - 12 mg/tablet | perindopril arginine/amlodipine | 02451557 | Hypertension | 05 Apr 2016 | Within Guidelines |
2016 | Servier Canada Inc. | Viacoram 14/10 - 24 mg/tablet | perindopril arginine/amlodipine | 02451549 | Hypertension | 05 Apr 2016 | Within Guidelines |
2016 | Takeda Canada Inc. | Ninlaro - 2.3 mg/capsule | ixazomib citrate | 02456796 | Cancer | 21 Sep 2016 | Within Guidelines |
2016 | Takeda Canada Inc. | Ninlaro - 3 mg/capsule | ixazomib citrate | 02456818 | Cancer | 21 Sep 2016 | Within Guidelines |
2016 | Takeda Canada Inc. | Ninlaro - 4 mg/capsule | ixazomib citrate | 02456826 | Cancer | 21 Sep 2016 | Within Guidelines |
2016 | Teva Canada Innovation G.P.-S.E.N.C | Copaxone - 40 mg/mL | glatiramer acetate | 02456915 | Mutiple Sclerosis | 26 Aug 2016 | Does Not Trigger Investigation |
2016 | UCB Canada Inc. | Brivlera - 10 mg/tablet | brivaracetam | 02452936 | Epilepsy | 2 May 2016 | Within Guidelines |
2016 | UCB Canada Inc. | Brivlera - 25 mg/tablet | brivaracetam | 02452944 | Epilepsy | 2 May 2016 | Within Guidelines |
2016 | UCB Canada Inc. | Brivlera - 50 mg/tablet | brivaracetam | 02452952 | Epilepsy | 2 May 2016 | Within Guidelines |
2016 | UCB Canada Inc. | Brivlera - 75 mg/tablet | brivaracetam | 02452960 | Epilepsy | 2 May 2016 | Within Guidelines |
2016 | UCB Canada Inc. | Brivlera - 100 mg/tablet | brivaracetam | 02452979 | Epilepsy | 2 May 2016 | Within Guidelines |
2016 | Vertex Pharmaceuticals Canada Inc. | Orkambi 200/125 - 325 mg/tablet | lumacaftor / ivacaftor | 02451379 | Cystic Fibrosis | 27 Jan 2016 | Does Not Trigger Investigation |
2016 | ViiV Healthcare Ulc | Tivicay - 50 mg/tablet | dolutegravir | 02414945 | HIV | 8 Nov 2013 (Patented 26 Apr 2016) | Within Guidelines |